Balyasny Asset Management LLC Dynavax Technologies Corp Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$11.7 - $14.98 $1.61 Million - $2.06 Million	137,600 New	137,600 $1.71 Million
Q3 2023 Nov 14, 2023	SELL	$12.64 - $14.99 $3.21 Million - $3.81 Million	-254,176 Reduced 23.5%	827,502 $12.2 Million
Q2 2023 Aug 14, 2023	BUY	$9.85 - $13.17 $10.7 Million - $14.2 Million	1,081,678 New	1,081,678 $14 Million
Q2 2019 Aug 14, 2019	SELL	$3.65 - $7.89 $210,740 - $455,544	-57,737 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$7.08 - $12.09 $411,326 - $702,392	-58,097 Reduced 50.16%	57,737 $422,000
Q4 2018 Feb 14, 2019	BUY	$8.14 - $13.28 $516,963 - $843,399	63,509 Added 121.37%	115,834 $1.06 Million
Q3 2018 Nov 14, 2018	BUY	$11.85 - $16.0 $488,516 - $659,600	41,225 Added 371.4%	52,325 $649,000
Q2 2018 Aug 14, 2018	BUY	$15.15 - $20.75 $168,165 - $230,325	11,100 New	11,100 $169,000

274

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.57B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.